Get the Stockscreener App
2.66
13.39%
0.27
Purple Biotech Ltd Adr stock is traded at $2.66, with a volume of 60,751.
It is up +13.39% in the last 24 hours and up +12.92% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
See More
Previous Close:
$2.39
Open:
$2.42
24h Volume:
60,751
Relative Volume:
0.62
Market Cap:
$1.49B
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-2.9231
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
+13.02%
1M Performance:
+12.92%
6M Performance:
-19.23%
1Y Performance:
-84.14%
1-Day Range:
$2.31
$2.7695
1-Week Range:
$2.25
$2.7695
52-Week Range:
$2.00
$20.60
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
2.685 | 6.59M | 0 | -19.88M | -19.93M | -0.91 |
|
ONC
Beone Medicines Ltd Adr
|
245.90 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.64 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.00 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
H.C. Wainwright lifts Purple Biotech stock target to $34 By Investing.com - Investing.com India
Purple Biotech appoints Shai Lankry as new CFO By Investing.com - Investing.com South Africa
Purple Biotech appoints Shai Lankry as new CFO - Investing.com
PPG Industries, Inc [PPG] stock Downgrade by BofA Securities analyst, price target now $126 - dbtnews.com
Edison International [EIX] Is Currently -8.89 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Purple Biotech Ltd ADR [PPBT] moved down -5.16: Why It’s Important - dbtnews.com
Nextracker Inc (NXT) Stock: A Year of Market Fluctuations - investchronicle.com
RIO Stock: Exploring Rio Tinto plc ADR’s Growth - investchronicle.com
GoPro Inc Inc. (GPRO) Price Performance: A Technical Analysis Perspective - investchronicle.com
The Significance of Moving Averages in Purple Biotech Ltd ADR Inc. (PPBT) Price Performance - investchronicle.com
American Electric Power Company Inc (AEP) Stock: Navigating Drops and Gains - investchronicle.com
Today’s watch list includes Purple Biotech Ltd ADR (NASDAQ:PPBT) stock - uspostnews.com
Watch this stock’s price performance: Coty Inc (NYSE:COTY) - uspostnews.com
Danaher Corp: A Year of Highs, Lows, and Market Resilience - investchronicle.com
Udemy Inc (UDMY) deserves closer scrutiny - uspostnews.com
Do investors need to be concerned about FreightCar America Inc (RAIL)? - uspostnews.com
Post-Trade Analysis: Purple Biotech Ltd ADR (PPBT) Slides -1.85, Closing at 2.65 - DWinneX
Closing Bell Recap: WNS (Holdings) Limited (WNS) Ends at 59.25, Reflecting a -1.38 Downturn - DWinneX
UDR’s Stock Market Adventure: 0.46% YTD Growth Amidst Volatility - investchronicle.com
Okta Inc (OKTA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewswire Inc.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Yahoo Finance
Why Purple Biotech (PPBT) Stock Is Getting Hammered - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Market Data Center - Barron's
The FDA Just Approved Kitov's ConsensiNow What? (NASDAQ:PPBT) - Seeking Alpha
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):